OPN-2853

October 5, 2023 Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

AUTHORS Duska, et al
Programs OPN-2853

https://ascopubs.org/doi/abs/10.1200/PO.23.00235

April 14, 2023 Poster

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

AUTHORS Swisher, et al
Programs OPN-2853

October 15, 2021 Publication

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

AUTHORS Snyder, et al
Programs OPN-2853, OPN-51107

https://doi.org/10.3389/fonc.2021.760789

May 20, 2021 Poster

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

AUTHORS Gordon, et al
Programs OPN-2853

November 5, 2020 Poster

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

AUTHORS Mims, et al
Programs OPN-2853

July 28, 2020 Publication

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

AUTHORS Cummin, et al
Programs OPN-2853, OPN-51107

https://doi.org/10.1182/bloodadvances.2020002231

November 13, 2019 Poster

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AUTHORS Pemmaraju, et al
Programs OPN-2853

May 20, 2018 Poster

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

AUTHORS Patnaik, et al
Programs OPN-2853